Can we override clopidogrel resistance?
Pena
Ana
A
Institut de Cardiologie, INSERM, Université Paris, Hôpital Pitié-Salpêtrière, France.
Collet
Jean-Philippe
JP
Hulot
Jean-Sébastien
JS
Silvain
Johanne
J
Barthélémy
Olivier
O
Beygui
Farzin
F
Funck-Brentano
Christian
C
Montalescot
Gilles
G
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000502:physiology; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use; D001711:Biotransformation / Q000235:genetics; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D004351:Drug Resistance / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D010879:Piperazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D000068799:Prasugrel Hydrochloride; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011859:Radiography; D015607:Stents; D013876:Thiophenes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D013876:Thiophenes; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C118568:cytochrome P-450 CYP2D16 (guinea pig); D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine; D001241:Aspirin